@Article{or.2023.030266,
AUTHOR = {YOHKO YAMAZAKI, MANABU KAWADA, ISAO MOMOSE},
TITLE = {Deoxynortryptoquivaline: A unique antiprostate cancer agent},
JOURNAL = {Oncology Research},
VOLUME = {31},
YEAR = {2023},
NUMBER = {6},
PAGES = {845--853},
URL = {http://www.techscience.com/or/v31n6/54216},
ISSN = {1555-3906},
ABSTRACT = {The androgen receptor (AR) is a critical target in all the clinical stages of prostate cancer. To identify a new AR inhibitor, we constructed a new screening system using the androgen-dependent growth of prostate cancer cell lines as a screening indicator. We screened 50,000 culture broths of microorganisms using this screening system and found that the fermentation broth produced by a fungus inhibited androgen-dependent growth of human prostate cancer LNCaP cells without cytotoxicity. Purification of this culture medium was performed, and this resulted in deoxynortryptoquivaline (DNT) being identified as a novel inhibitor of AR function. DNT showed potent inhibition of androgen-dependent growth of human prostate cancer LNCaP cells. The AR competitor assay was performed, and DNT did not act as an AR antagonist. However, DNT inhibited AR-dependent transcriptional activity and AR nuclear translocation, it suggested that the suppression of AR function leads to inhibition activity against androgen-dependent growth.},
DOI = {10.32604/or.2023.030266}
}